Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 11/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.46 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4073239 | 0.87 | GRM5 (0.51) | GRM5MAPTLMNASMN1; SMN2HCRTR1 | |
| SCHEMBL4060315 | 0.85 | SMN1; SMN2 (0.40) | GRM5MAPTSMN1; SMN2 | |
| SCHEMBL5440803 | 0.82 | GRM5 (0.41) | GRM5MAPTSMN1; SMN2HCRTR1HCRTR2 | |
| SCHEMBL5398780 | 0.79 | KCNH2 (0.45) | GRM5MAPTLMNASMN1; SMN2HCRTR1 | |
| SCHEMBL5483157 | 0.79 | MAPT (0.43) | GRM5MAPTLMNASMN1; SMN2HCRTR1 | |
| SCHEMBL5485899 | 0.79 | MAPT (0.43) | GRM5MAPTLMNASMN1; SMN2HCRTR1 | |
| SCHEMBL5438651 | 0.79 | MAPT (0.43) | GRM5MAPTLMNASMN1; SMN2HCRTR1 | |
| SCHEMBL4074105 | 0.77 | GRM5 (0.43) | GRM5SMN1; SMN2 | |
| SCHEMBL3961869 | 0.77 | GRM5 (0.43) | GRM5SMN1; SMN2 | |
| SCHEMBL3961132 | 0.77 | GRM5 (0.43) | GRM5SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101437798-A | Mglur5 modulators II | ASTRAZENECA AB (SE) | 2009-05-20 | — | — | CN | claimed |
| EP-2027090-A2 | MGLUR5 MODULATORS II | AstraZeneca AB (SE) | 2009-02-25 | — | — | EP | claimed |
| WO-2007130821-A2 | MGLUR5 MODULATORS II | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | claimed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | claimed |
| WO-2007130821-A2 | MGLUR5 MODULATORS II | ASTRAZENECA AB (SE) | 2007-11-15 | — | — | WO | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
| US-20070259916-A1 | mGluR5 modulators II | ASTRAZENECA AB (SE) | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259916-A1 | mGluR5 modulators II | GRM5, GRM2, GRIK5 | GRM5 1/4885MAPT 797/4885LMNA 4579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.